Influenza

The case occurred to a man in Colorado who had direct contact with cattle and state public health officials offer details on the patient as well as the risk to the public.

Recent studies in Emerging Infectious Diseases have highlighted the persistence of highly pathogenic avian influenza A (H5N1) virus on milking equipment surfaces and its presence in dairy cattle mammary glands.

Michigan is taking decisive action to support dairy farms affected by the recent outbreak of highly pathogenic avian influenza (HPAI).

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

This man was the first person globally to have been diagnosed with influenza A(H5N2).

This is the second case in Michigan and it is confirmed in another farmworker who worked with infected cattle.

In a human challenge, an investigational spray, Neumifil (HEX17), manufactured by Pneumagen, reported its results at the recent American Thoracic Society meeting.

A Michigan farmworker who had regular contact with livestock was confirmed to have contracted the virus.

Both the World Health Organization and FDA have now recommended this particular set of viruses be left off influenza vaccines for the 2024-2025 respiratory virus season. A new study points to further evidence of their extinction.

A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.

The accuracy of ICD-10 varied depending on the patient's age, how the influenza season was defined, the time interval between symptom onset and testing, and the clinical setting.

The Department of Agriculture has initiated proactive measures, collaborating with federal agencies, to ensure the safety of the nation's meat supply.

A study presented at ESCMID examines the efficacy and safety of the vaccine in older populations.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

Already FDA-approved in the US, TG-1000 confirms safety and prepares for global expansion.

Trial examines high-dose vs. standard-dose influenza vaccines.

Evaluating the importance of RSV vaccination implications for adults.

Emergency use authorization for CorDx TyFast Flu A/B & COVID-19.

The case was confirmed in Texas and the person was in contact with cows. CDC says the risk for infection remains low.

A large European study looked at a modern-day communication method and its influence on a public health initiative to increase immunizations.

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.

Public health strategy in navigating flu season.

A recent study reveals the QIV-HD vaccine significantly lowers hospitalization rates compared to the standard-dose vaccine (QIV-SD).

Phase 2 study for the investigational antiviral, ZSP1273 (onradivir), demonstrated safety and efficacy in reducing the time to resolution of symptoms in a multicenter trial.

Though more research is needed to determine reasons for the association, a study published in JAMA Network revealed the 2021-2022 influenza season was associated with a significantly higher household transmission risk compared to pre-pandemic seasons.

In 43 of 154 school weeks, air samples were positive for influenza A virus (IAV) while SARS-CoV-2 was positive in air samples in 101 of 154 school weeks.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

Last year was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic.

Overall, the study authors concluded that the immunogenicity of QIV and TIV was similar for common influenza ingredients for children aged 6 to 35 months.

The interim analysis of its phase 3 study shows the company’s mRNA-1010 vaccine was efficacious against all 4 A and B influenza strains.